Portage Historical Balance Sheet

PRTG Stock

USD 4.41 0.15 3.29%

Trend analysis of Portage Biotech balance sheet accounts such as Property Plant And Equipment Net of 38.2 K, Cash of 3.2 M, Non Current Assets Total of 91.8 K or Cash And Short Term Investments of 6.1 M provides information on Portage Biotech's total assets, liabilities, and equity, which is the actual value of Portage Biotech to its prevalent stockholders. By breaking down trends over time using Portage Biotech balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Portage Biotech latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Portage Biotech is a good buy for the upcoming year.

Portage Biotech Inventory

(1.28 Million)

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Portage Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more detail on how to invest in Portage Stock please use our How to Invest in Portage Biotech guide.

About Portage Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Portage Biotech at a specified time, usually calculated after every quarter, six months, or one year. Portage Biotech Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Portage Biotech and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Portage currently owns. An asset can also be divided into two categories, current and non-current.

Portage Biotech Balance Sheet Chart

At this time, Portage Biotech's Cash And Short Term Investments are most likely to increase significantly in the upcoming years. The Portage Biotech's current Common Stock Shares Outstanding is estimated to increase to about 24.6 M, while Total Stockholder Equity is projected to decrease to roughly 4.4 M.

Total Assets Total Current Liabilities Non Current Assets Total Cash And Short Term Investments

Add Fundamental

Total Assets

Total assets refers to the total amount of Portage Biotech assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Portage Biotech books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Portage Biotech balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Portage Biotech are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Non Current Assets Total

The total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets.

Cash And Short Term Investments

Short Term Investments is an account in the current assets section of Portage Biotech balance sheet. This account contains Portage Biotech investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Portage Biotech fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.

Most accounts from Portage Biotech's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Portage Biotech current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Portage Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more detail on how to invest in Portage Stock please use our How to Invest in Portage Biotech guide.At this time, Portage Biotech's Cash And Short Term Investments are most likely to increase significantly in the upcoming years. The Portage Biotech's current Common Stock Shares Outstanding is estimated to increase to about 24.6 M, while Total Stockholder Equity is projected to decrease to roughly 4.4 M.

	2022	2023	2024	2025 (projected)
Non Current Assets Total	85.5M	84K	96.6K	91.8K
Cash	10.5M	5.0M	5.8M	3.2M

Non Current Assets Total Cash

Portage Biotech balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Short Long Term Debt Total	Non Currrent Assets Other	Other Assets	Non Current Liabilities Total	Other Current Assets	Short Term Debt	Accounts Payable	Net Receivables	Inventory	Intangible Assets	Good Will
Total Assets		0.1	0.21	0.99	-0.64	-0.37	0.19	0.51	0.98	0.19	0.16	-0.17	0.95	0.19	0.25	0.58	-0.05	0.94	0.97	-0.16	-0.22	-0.25	0.41	-0.23	0.66	0.78
Other Current Liab	0.1		0.94	0.05	0.33	0.07	-0.68	-0.08	0.13	-0.26	0.72	0.6	0.28	-0.17	0.71	-0.08	-0.13	0.11	0.18	0.74	-0.63	0.21	0.38	-0.71	0.28	-0.05
Total Current Liabilities	0.21	0.94		0.14	0.26	0.1	-0.69	-0.06	0.25	-0.31	0.76	0.5	0.39	-0.23	0.78	0.16	-0.2	0.25	0.28	0.66	-0.57	0.35	0.29	-0.65	0.36	0.04
Total Stockholder Equity	0.99	0.05	0.14		-0.68	-0.41	0.19	0.53	0.94	0.33	0.15	-0.16	0.92	0.33	0.24	0.51	0.01	0.88	0.94	-0.16	-0.21	-0.3	0.4	-0.23	0.69	0.72
Property Plant And Equipment Net	-0.64	0.33	0.26	-0.68		0.27	-0.45	-0.35	-0.59	-0.35	0.17	0.42	-0.52	-0.32	0.15	-0.35	-0.34	-0.51	-0.57	0.44	-0.21	0.23	-0.22	-0.16	-0.48	-0.59
Net Debt	-0.37	0.07	0.1	-0.41	0.27		0.22	-0.97	-0.34	-0.17	-0.33	-0.18	-0.42	-0.18	-0.37	0.25	-0.28	-0.26	-0.45	-0.03	0.38	0.14	-0.01	0.52	-0.32	-0.3
Retained Earnings	0.19	-0.68	-0.69	0.19	-0.45	0.22		-0.19	0.17	0.17	-0.89	-0.5	-0.04	0.12	-0.89	0.26	-0.05	0.24	0.05	-0.53	0.68	-0.4	0.07	0.77	-0.22	0.36
Cash	0.51	-0.08	-0.06	0.53	-0.35	-0.97	-0.19		0.49	0.16	0.33	0.12	0.55	0.16	0.39	-0.04	0.26	0.41	0.58	-0.02	-0.36	-0.1	-0.03	-0.47	0.42	0.43
Non Current Assets Total	0.98	0.13	0.25	0.94	-0.59	-0.34	0.17	0.49		0.01	0.16	-0.17	0.97	0.01	0.26	0.61	-0.06	0.96	0.98	-0.15	-0.24	-0.19	0.44	-0.23	0.59	0.8
Cash And Short Term Investments	0.19	-0.26	-0.31	0.33	-0.35	-0.17	0.17	0.16	0.01		-0.03	-0.15	0.0	0.99	-0.06	-0.11	0.01	0.0	0.03	-0.18	0.1	-0.35	-0.15	0.03	0.43	-0.04
Common Stock Shares Outstanding	0.16	0.72	0.76	0.15	0.17	-0.33	-0.89	0.33	0.16	-0.03		0.31	0.35	0.0	0.97	-0.07	0.0	0.1	0.26	0.39	-0.78	0.23	0.08	-0.84	0.52	-0.05
Other Stockholder Equity	-0.17	0.6	0.5	-0.16	0.42	-0.18	-0.5	0.12	-0.17	-0.15	0.31		-0.02	-0.02	0.36	-0.34	-0.03	-0.22	-0.08	0.94	-0.21	0.41	0.02	-0.47	-0.16	-0.33
Total Liab	0.95	0.28	0.39	0.92	-0.52	-0.42	-0.04	0.55	0.97	0.0	0.35	-0.02		0.02	0.46	0.52	0.03	0.88	0.99	0.0	-0.4	-0.14	0.45	-0.41	0.63	0.7
Total Current Assets	0.19	-0.17	-0.23	0.33	-0.32	-0.18	0.12	0.16	0.01	0.99	0.0	-0.02	0.02		-0.02	-0.14	0.02	-0.01	0.04	-0.05	0.08	-0.32	-0.13	-0.03	0.43	-0.06
Common Stock	0.25	0.71	0.78	0.24	0.15	-0.37	-0.89	0.39	0.26	-0.06	0.97	0.36	0.46	-0.02		0.02	0.03	0.18	0.37	0.43	-0.77	0.25	0.09	-0.84	0.54	0.0
Short Long Term Debt Total	0.58	-0.08	0.16	0.51	-0.35	0.25	0.26	-0.04	0.61	-0.11	-0.07	-0.34	0.52	-0.14	0.02		-0.15	0.65	0.53	-0.26	0.19	0.13	-0.16	0.37	0.36	0.57
Non Currrent Assets Other	-0.05	-0.13	-0.2	0.01	-0.34	-0.28	-0.05	0.26	-0.06	0.01	0.0	-0.03	0.03	0.02	0.03	-0.15		-0.23	0.06	-0.04	0.04	-0.24	0.04	-0.04	0.24	0.15
Other Assets	0.94	0.11	0.25	0.88	-0.51	-0.26	0.24	0.41	0.96	0.0	0.1	-0.22	0.88	-0.01	0.18	0.65	-0.23		0.88	-0.19	-0.16	-0.17	0.38	-0.13	0.58	0.86
Non Current Liabilities Total	0.97	0.18	0.28	0.94	-0.57	-0.45	0.05	0.58	0.98	0.03	0.26	-0.08	0.99	0.04	0.37	0.53	0.06	0.88		-0.08	-0.34	-0.18	0.43	-0.35	0.6	0.72
Other Current Assets	-0.16	0.74	0.66	-0.16	0.44	-0.03	-0.53	-0.02	-0.15	-0.18	0.39	0.94	0.0	-0.05	0.43	-0.26	-0.04	-0.19	-0.08		-0.27	0.33	0.07	-0.5	-0.05	-0.28
Short Term Debt	-0.22	-0.63	-0.57	-0.21	-0.21	0.38	0.68	-0.36	-0.24	0.1	-0.78	-0.21	-0.4	0.08	-0.77	0.19	0.04	-0.16	-0.34	-0.27		0.12	-0.29	0.86	-0.34	0.01
Accounts Payable	-0.25	0.21	0.35	-0.3	0.23	0.14	-0.4	-0.1	-0.19	-0.35	0.23	0.41	-0.14	-0.32	0.25	0.13	-0.24	-0.17	-0.18	0.33	0.12		-0.39	-0.01	-0.24	-0.31
Net Receivables	0.41	0.38	0.29	0.4	-0.22	-0.01	0.07	-0.03	0.44	-0.15	0.08	0.02	0.45	-0.13	0.09	-0.16	0.04	0.38	0.43	0.07	-0.29	-0.39		-0.41	0.16	0.29
Inventory	-0.23	-0.71	-0.65	-0.23	-0.16	0.52	0.77	-0.47	-0.23	0.03	-0.84	-0.47	-0.41	-0.03	-0.84	0.37	-0.04	-0.13	-0.35	-0.5	0.86	-0.01	-0.41		-0.39	0.03
Intangible Assets	0.66	0.28	0.36	0.69	-0.48	-0.32	-0.22	0.42	0.59	0.43	0.52	-0.16	0.63	0.43	0.54	0.36	0.24	0.58	0.6	-0.05	-0.34	-0.24	0.16	-0.39		0.62
Good Will	0.78	-0.05	0.04	0.72	-0.59	-0.3	0.36	0.43	0.8	-0.04	-0.05	-0.33	0.7	-0.06	0.0	0.57	0.15	0.86	0.72	-0.28	0.01	-0.31	0.29	0.03	0.62

Click cells to compare fundamentals

Portage Biotech Account Relationship Matchups

Portage Biotech balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	174.9M	194.7M	99.1M	7.8M	8.9M	8.5M
Other Current Liab	2.9M	595K	1.6M	2.4M	2.7M	2.8M
Total Current Liabilities	3.2M	783K	1.9M	2.9M	3.3M	3.5M
Total Stockholder Equity	101.4M	121.2M	76.0M	4.0M	4.6M	4.4M
Net Debt	(2.6M)	(23.4M)	(10.5M)	(5.0M)	(4.5M)	(4.3M)
Retained Earnings	(38.1M)	(55.0M)	(159.6M)	(239.3M)	(215.4M)	(204.6M)
Cash	2.8M	23.4M	10.5M	5.0M	5.8M	3.2M
Non Current Assets Total	169.9M	169.8M	85.5M	84K	96.6K	91.8K
Cash And Short Term Investments	2.8M	23.4M	10.5M	5.0M	5.8M	6.1M
Common Stock Shares Outstanding	11.7M	13.1M	16.1M	20.3M	23.4M	24.6M
Liabilities And Stockholders Equity	174.9M	194.7M	99.1M	7.8M	8.9M	8.5M
Other Stockholder Equity	58K	8.0M	16.9M	21.2M	24.4M	13.3M
Total Liab	27.3M	29.2M	23.7M	4.5M	5.1M	6.1M
Total Current Assets	4.9M	24.8M	13.7M	7.7M	8.8M	7.1M
Common Stock	130.6M	158.3M	218.8M	219.5M	252.4M	265.0M
Short Long Term Debt Total	3.7M	3.7M	150K	47K	54.1K	51.3K
Non Currrent Assets Other	58K	36K	877K	49K	44.1K	41.9K
Other Assets	117.4M	117.4M	117.4M	1.0	1.15	1.09
Non Current Liabilities Total	24.1M	28.4M	21.9M	1.6M	1.8M	1.7M
Other Current Assets	1.5M	1.3M	2.4M	2.6M	3.0M	3.2M
Accounts Payable	113K	188K	274K	482K	554.3K	304.4K
Net Receivables	2.2M	209K	682K	39K	44.9K	42.6K
Net Tangible Assets	56.4M	53.2M	58.1M	77.9M	89.6M	57.7M
Long Term Investments	6.4M	8.6M	9.1M	9.1M	2.9M	0.0
Net Invested Capital	101.6M	121.2M	76.0M	4.0M	3.6M	3.4M
Net Working Capital	1.7M	24.0M	11.8M	4.8M	5.5M	8.8M
Capital Stock	130.6M	158.3M	218.8M	219.5M	252.4M	176.2M

Currently Active Assets on Macroaxis

EBR	Centrais Electricas Brasileiras
HE	Hawaiian Electric Industries
VFC	VF Corporation
BVHMF	Vistry Group PLC
S	SentinelOne

When determining whether Portage Biotech is a strong investment it is important to analyze Portage Biotech's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Portage Biotech's future performance. For an informed investment choice regarding Portage Stock, refer to the following important reports:

How To Invest In Portage

Details

Is Portage Stock a good investment?

Details

What is Portage Biotech's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For more detail on how to invest in Portage Stock please use our How to Invest in Portage Biotech guide.

You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Portage Biotech. If investors know Portage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Portage Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(68.17)

Return On Assets

(0.19)

Return On Equity

(1.91)

The market value of Portage Biotech is measured differently than its book value, which is the value of Portage that is recorded on the company's balance sheet. Investors also form their own opinion of Portage Biotech's value that differs from its market value or its book value, called intrinsic value, which is Portage Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Portage Biotech's market value can be influenced by many factors that don't directly affect Portage Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Portage Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Portage Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Portage Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Portage Historical Balance Sheet

Portage Biotech Inventory

(1.28 Million)

About Portage Balance Sheet Analysis

Portage Biotech Balance Sheet Chart

Total Assets

Total Current Liabilities

Non Current Assets Total

Cash And Short Term Investments

Portage Biotech balance sheet Correlations

Portage Biotech Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Portage Biotech balance sheet Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Cash And Short Term Investments
Non Current Liabilities Total	+ 0.99	Total Liab
Non Current Assets Total	+ 0.98	Total Assets
Non Current Liabilities Total	+ 0.98	Non Current Assets Total
Non Current Liabilities Total	+ 0.97	Total Assets

Cash	- 0.97	Net Debt
Common Stock	- 0.89	Retained Earnings
Common Stock Shares Outstanding	- 0.89	Retained Earnings
Inventory	- 0.84	Common Stock
Inventory	- 0.84	Common Stock Shares Outstanding
Short Term Debt	- 0.78	Common Stock Shares Outstanding